Literature DB >> 25970056

Treatment of HER2-positive metastatic breast cancer.

Sandra M Swain, Emma Clark, José Baselga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25970056      PMCID： PMC4980989          DOI： 10.1056/NEJMc1503446

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1 in total

1.  Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.

Authors:  Denise A Yardley; Peter A Kaufman; Adam Brufsky; Marianne Ulcickas Yood; Hope Rugo; Musa Mayer; Cheng Quah; Bongin Yoo; Debu Tripathy
Journal:  Breast Cancer Res Treat       Date:  2014-04-06       Impact factor: 4.872
  1 in total
  8 in total

Review 1.  HER3 in cancer: from the bench to the bedside.

Authors:  Lucía Gandullo-Sánchez; Alberto Ocaña; Atanasio Pandiella
Journal:  J Exp Clin Cancer Res       Date:  2022-10-21

2.  Effects of Surgical Intervention for Bone Metastases on Survival in Patients with Advanced Cancer: A Nationwide Population-Based Cohort Study.

Authors:  Jen-Ta Shih; Tsu-Te Yeh; Pei-Hung Shen; Chih-Chien Wang; Sheng-Hao Wang; Wu-Chien Chien; Chi-Hsiang Chung; Chia-Chun Wu
Journal:  Int J Gen Med       Date:  2021-05-03

3.  Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.

Authors:  Begoña Martin-Castillo; Eugeni Lopez-Bonet; Elisabet Cuyàs; Gemma Viñas; Sonia Pernas; Joan Dorca; Javier A Menendez
Journal:  Oncotarget       Date:  2015-10-20

Review 4.  ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.

Authors:  Nico Jacobi; Rita Seeboeck; Elisabeth Hofmann; Andreas Eger
Journal:  Cancers (Basel)       Date:  2017-04-12       Impact factor: 6.639

Review 5.  Nanomaterials-Tools, Technology and Methodology of Nanotechnology Based Biomedical Systems for Diagnostics and Therapy.

Authors:  Christian Schmidt; Joachim Storsberg
Journal:  Biomedicines       Date:  2015-07-20

6.  Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.

Authors:  Minati Satpathy; Liya Wang; Rafal J Zielinski; Weiping Qian; Y Andrew Wang; Aaron M Mohs; Brad A Kairdolf; Xin Ji; Jacek Capala; Malgorzata Lipowska; Shuming Nie; Hui Mao; Lily Yang
Journal:  Theranostics       Date:  2019-01-24       Impact factor: 11.556

7.  SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer.

Authors:  Lauren L Siewertsz van Reesema; Vasilena Zheleva; Janet S Winston; Rick J Jansen; Carolyn F O'Connor; Andrew J Isbell; Minglei Bian; Rui Qin; Patricia T Bassett; Virginia J Hinson; Kimberly A Dorsch; Brad W Kirby; Robert E Van Sciver; Angela M Tang-Tan; Elizabeth A Harden; David Z Chang; Cynthia A Allen; Roger R Perry; Richard A Hoefer; Amy H Tang
Journal:  EBioMedicine       Date:  2016-08-14       Impact factor: 8.143

Review 8.  Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer.

Authors:  Babak Nami; Hamid Maadi; Zhixiang Wang
Journal:  Cancers (Basel)       Date:  2018-09-20       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.